Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 2 | Unknown | — |
The second of Vivotif was due on Friday but forgot to take and only took it on Sunday, four days after first dose; Case reference number US-BN-2025-001032 is a spontaneous case initially received from consumer via Communications (reference number: USBAV25-1359) on 09-Jun-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 04-Jun-2025 Wednesday, the patient took first dose of Vivotif (batch number: unknown) at unknown doses, or route of administration for unknown indication. On 08-Jun-2025 on Sunday, as reported dose was due on Friday, but the patient forgot, and four days after first dose the patient took second dose of Vivotif (batch number: unknown) at unknown doses, or route of administration (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse event. No further information was provided.; Reporter's Comments: This case report concerns a female patient of unspecified age, who has received second dose of Vivotif, after four days from the first dose of Vivotif vaccination for unknown indication, which is considered as inappropriate schedule of product administration. Inappropriate schedule of product administration is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Patient's relevant medical history and concomitant medications were not reported. Causality is assessed as not related to suspect vaccine, but to human factor. The case is non-serious.; Sender's Comments: This case report concerns a female patient of unspecified age, who has received second dose of Vivotif, after four days from the first dose of Vivotif vaccination for unknown indication, which is considered as inappropriate schedule of product administration. Inappropriate schedule of product administration is considered as listed per company convention. At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif. Patient's relevant medical history and concomitant medications were not reported. Causality is assessed as not related to suspect vaccine, but to human factor. The case is non-serious.
Comments: None.